1. Home
  2. SCYX vs CNVS Comparison

SCYX vs CNVS Comparison

Compare SCYX & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • CNVS
  • Stock Information
  • Founded
  • SCYX 1999
  • CNVS 2000
  • Country
  • SCYX United States
  • CNVS United States
  • Employees
  • SCYX N/A
  • CNVS N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • CNVS Consumer Electronics/Video Chains
  • Sector
  • SCYX Health Care
  • CNVS Consumer Discretionary
  • Exchange
  • SCYX Nasdaq
  • CNVS Nasdaq
  • Market Cap
  • SCYX 50.3M
  • CNVS 57.8M
  • IPO Year
  • SCYX 2014
  • CNVS 2003
  • Fundamental
  • Price
  • SCYX $1.02
  • CNVS $3.96
  • Analyst Decision
  • SCYX Buy
  • CNVS Buy
  • Analyst Count
  • SCYX 1
  • CNVS 1
  • Target Price
  • SCYX N/A
  • CNVS $10.00
  • AVG Volume (30 Days)
  • SCYX 210.1K
  • CNVS 178.2K
  • Earning Date
  • SCYX 11-06-2024
  • CNVS 02-12-2025
  • Dividend Yield
  • SCYX N/A
  • CNVS N/A
  • EPS Growth
  • SCYX N/A
  • CNVS N/A
  • EPS
  • SCYX N/A
  • CNVS N/A
  • Revenue
  • SCYX $8,566,000.00
  • CNVS $45,005,000.00
  • Revenue This Year
  • SCYX N/A
  • CNVS $50.96
  • Revenue Next Year
  • SCYX $405.82
  • CNVS N/A
  • P/E Ratio
  • SCYX N/A
  • CNVS N/A
  • Revenue Growth
  • SCYX N/A
  • CNVS N/A
  • 52 Week Low
  • SCYX $0.90
  • CNVS $0.72
  • 52 Week High
  • SCYX $3.07
  • CNVS $4.19
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 34.82
  • CNVS 61.91
  • Support Level
  • SCYX $0.90
  • CNVS $3.16
  • Resistance Level
  • SCYX $1.04
  • CNVS $3.56
  • Average True Range (ATR)
  • SCYX 0.07
  • CNVS 0.29
  • MACD
  • SCYX -0.01
  • CNVS -0.02
  • Stochastic Oscillator
  • SCYX 34.10
  • CNVS 89.89

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About CNVS Cineverse Corp.

Cineverse Corp is a main streaming technology and entertainment company. It operates portfolios of owned and operated streaming channels, all powered by its, proprietary technology platform. Cineverse features enthusiast brands for subscription video on demand (SVOD), advertising-based video on demand (AVOD), and free, ad-supported streaming television (FAST) channels. The company earns fees for the distribution of content in the home entertainment markets via several distribution channels, including digital, video-on-demand, and physical goods (e.g., DVDs and Blu-ray Discs) (Base Distribution).

Share on Social Networks: